[1] ROMANO M,DE FRANCESCO F,GRINGERI E,et al. Tumor microenvironment versus cancer stem cells in cholangiocarcinoma:Synergistic effects?[J]. J Cell Physiol,2016,231(4):768-776.
[2] Reya T,Morrison S J,Clarke M F,et al. Stem cells,cancer,and cancer stem cells[J]. Nature,2011,414(6859):105-111.
[3] BAUTISTA W,PEREZ-ALVAREZ V,BURCZYNSKI F,et al. Membrane potential differences and GABAA receptor expression in hepatic tumor and non-tumor stem cells[J]. Can J Physiol Pharmacol,2014,92(1):85-91.
[4] JIAO X L,ZHAO C,NIU M,et al. Downregulation of CD24 inhibits invasive growth,facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells[J]. Eur Rev Med Pharmacol Sci,2013,17(13):1709-1715.
[5] LEE T K,CASTILHO A,CHEUNG V C,et al. CD24(+) liver tumorinitiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation[J]. Cell Stem Cell,2011,9(1):50-63.
[6] KIM K,MIN HS,CHIE EK,et al. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer[J]. World J Gastroenterol,2013,19(9):1438-1443.
[7] KEERATICHAMROEN S,LEELAWAT K,THONGTAWEE T,et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival[J]. Int J Oncol,2011,39(4):873-881.
[8] LEE HJ,CHOE G,JHEON S,et al. CD24,a novel cancer biomarker,predicting disease-free survival of non-small cell lung carcinomas:are trospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification[J]. J Thorac Oncol,2010,5(5):649-657.
[9] WILLIAMS K,MOTIANI K,GIRIDHAR P V,et al. CD44 integrates signaling in normal stem cell,cancer stem cell and (pre) metastatic niches[J].Exp Biol Med (Maywood),2013,238(3):324-338.
[10] ORIAN-ROUSSEAU V. CD44 acts as a signaling platform controlling tumor progression and metastasis[J]. Front Immunol,2015,6(1):154.
[11] THOMPSON S M,CALLSTROM M R,BUTTERS K A,et al. Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation:in vitro and in vivo pilot study[J]. Cardiovasc Intervent Radiol,2014,37(5):1343-1351.
[12] MALINEE T,WATCHARIN L,ANCHALEE T,et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangio-carcinoma:A target for cholangiocarcinoma treatment[J]. Cancer Sci,2016,107(7):991-1000.
[13] THANAN R,PAIROJKUL C,PINLAOR S,et al. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangio-carcinoma patients with poor prognosis[J]. Free Radic Biol Med,2013,65(1):1464-1472.
[14] CHU X,ZHAO P,LV Y,et al. Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma[J]. Int J Clin Exp Pathol,2015,8(1):328-336.
[15] AHMED H G,ABDUL G S R,ABD E A M,et al. Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications[J]. Asian Pac J Cancer Prev,2015,16(2):653-656.
[16] ZHAO Q,YU W L,LU X Y,et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone:a pathomolecular evidence-based study[J]. Chin J Cancer,2016,35(1):82.
[17] WELINDER C,JANSSON B,LINDELL G,et al. Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer[J]. Cancer Lett,2015,358(1):43-46.
[18] BONIN S,PRACELLA D,BARBAZZA R,et al.In stage Ⅱ/Ⅲ lymph node-positive breast cancer patients less than 55 years of age,keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival[J]. Virchows Arch,2015,466(5):571-580.
[19] RADZISHEUSKAYA A,CHIA GLE B,DOS SANTOS RL,et al. A defined Oct4 level governs cell state transitions of pluripotency entry and differentiation into all embryonic lineages[J]. Nat Cell Biol,2013,15(6):579-590.
[20] KAROUBI G,CORTES-DERICKS L,GUGGER M,et al. Atypical expression and distribution of embryonic stem cell marker,OCT4,in human lung adenocarcinoma[J]. J Surg Oncol,2010,102(6):689-698.
[21] HU J,QIU M,JIANG F,et al. MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells[J]. Tumour Biol,2014,35(9):8953-8961.
[22] GAO L,YANG Y,XU H,et al. MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4[J]. Tumour Biol,2014,35(8):8309-8318.
[23] WEIKUM E R,TUNTLAND M L,MURPHY M N,et al. A structural investigation into Oct4 regulation by orphan nuclear receptors,germ cell nuclear factor (GCNF) and liver receptor homolog-1(LRH-1)[J]. J Mol Biol,2016,36(16):2981-4992.
[24] 谷化平,黄勇,尚培中. 干细胞转录因子Oct4和CD133蛋白在肝外胆管癌组织中的表达及临床意义[J]. 中国现代普通外科杂志,2014,17(2):112-115.
[25] SHOLL L M,LONG K B,HORNICK J L. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas[J]. Appl Immuno-histochem Mol Morphol,2010,18(1):55-61.
[26] BOURGUIGNON L Y,WONG G,EARLE C,et al. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal,clonal formation,and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma[J]. J Biol Chem,2012,287(39):32800-32824.
[27] MATSUOKA J,YASHIRO M,SAKURAI K,et al. Role of the stemness factors sox2,oct3/4,and nanog in gastric carcinoma[J]. J Surg Res,2012,174(1):130-135.
[28] SUN Q,LI J,WANG G,et al. Role of the embryonic protein SOX2 in cholangiocarcinoma[J]. Cell Biochem Biophys,2014,70(2):1311-1316.
[29] LIN Y L,HAN Z B,XIONG F Y,et al. Malignant transformation of 293 cells induced by ectopic expression of human Nanog[J]. Mol Cell Biochem,2011,351(1/2):109-116.
[30] SUN C,SUN L,JIANG K,et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transitionthrough NODAL/SMAD3 signaling pathway[J]. Int J Biochem Cell Biol,2013,45(6):1099-1108.
[31] CAVALLONI G,PERALDO-NEIA C,VARAMO C,et al. Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient[J]. Tumour Biol,2016,37(3):4041-4052.
[32] GUO Q,JIAN Z,JIA B,et al. CXCL7 promotes proliferation and invasion of cholangiocarcinoma cells[J]. Oncol Rep,2017,37(2):1114-1122.
[33] SULLIVAN J P,SPINOLA M,DODGE M,et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling[J]. Cancer Res,2010,70(23):9937-9948.
[34] SHUANG Z Y,WU W C,XU J,et al. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma[J]. Cancer Lett,2014,354(2):320-328.
[35] LIU D C,YANG Z L,JIANG S,et al. Identification of musashi-1 and ALDH1 as carcinogenesis,progression,and poor-prognosis related biomarkers for gallbladder adenocarcinoma[J]. Cancer Biomark,2011,8(3):113-121.
[36] GUO Z,LI L Q,JIANG J H,et al. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma[J]. World J Gastroenterol,2014,20(8):2098-2106.
|
